Biodexa Pharmaceuticals (BDRX) Accumulated Expenses (2014 - 2017)

Biodexa Pharmaceuticals has disclosed Accumulated Expenses across 4 years of filings, most recently posting $4.1 million for Q4 2017.

• In Q4 2017, Accumulated Expenses rose 64.75% year-over-year to $4.1 million; the TTM figure through Dec 2017 stood at $4.1 million (up 64.75% YoY), while the FY2017 annual figure was $4.0 million, up 46.49% from the prior year.
• Accumulated Expenses came in at $4.1 million for Q4 2017 at Biodexa Pharmaceuticals, up from $2.5 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $4.7 million in Q4 2015 to a low of $1.2 million in Q4 2014.
• Average Accumulated Expenses over 4 years is $3.1 million, with a median of $3.3 million recorded in 2016.
• Year-over-year, Accumulated Expenses jumped 305.74% in 2015 and slumped 47.08% in 2016.
• Over 4 years, Accumulated Expenses stood at $1.2 million in 2014, then jumped by 305.74% to $4.7 million in 2015, then sank by 47.08% to $2.5 million in 2016, then surged by 64.75% to $4.1 million in 2017.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $4.1 million in Q4 2017, $2.5 million in Q4 2016, and $4.7 million in Q4 2015.